KPA opposes further expansion of exceptional SDP function

Published: 2003-09-02 06:56:00

Updated: 2003-09-02 06:56:00

The Korea Pharmaceutical Association said recently that it opposes the proposed Pharmaceutical Affairs Law's revision plan to exceptionally expand the current SDP function to patients with national merits and those who have suffered from sequelae of orange agents, noting that the plan will impair...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK